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Abstract
Plasmodium falciparum rosetting (the spontaneous binding of infected erythrocytes to uninfected
erythrocytes) is a well-recognized parasite virulence factor. However, it is currently unclear
whether rosetting is associated with all clinical forms of severe malaria, or only with specific
syndromes such as cerebral malaria. We investigated the relationship between rosetting and
clinical malaria in 209 Malian children enrolled in a case-control study of severe malaria.
Rosetting was significantly higher in parasite isolates from severe malaria cases compared with
non-severe hyperparasitemia and uncomplicated malaria controls (F2,117 = 8.15, P < 0.001).
Analysis of sub-categories of severe malaria (unrousable coma, severe anemia, non-comatose
neurological impairment, repeated seizures or a small heterogeneous group with signs of renal
failure or jaundice) showed high levels of rosetting in all sub-categories, and no statistically
significant differences in rosetting between sub-categories (F4,67 = 1.28, P = 0.28). Thus rosetting
may contribute to the pathogenesis of all severe malaria syndromes in African children, and
interventions to disrupt rosetting could be potential adjunctive therapies for all forms of severe
malaria in Africa.
INTRODUCTION
The binding of P. falciparum infected erythrocytes to uninfected erythrocytes to form
clusters of cells called rosettes is a parasite adhesion property that varies between isolates
and is associated with malaria severity in numerous sub-Saharan African studies.1-9
Experimental models suggest that rosetting enhances microvascular obstruction,10 which is
thought to be a key pathological process in severe malaria.11,12 Genetic epidemiological
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studies show that human erythrocyte polymorphisms that reduce the ability of P. falciparum
to form rosettes (such as complement receptor 1 deficiency13 and blood group O)4,14 confer
protection against severe malaria, reducing the odds ratio for severe disease by about two-
thirds.15,16 Taken together, these data support the hypothesis that rosetting contributes to the
pathogenesis of severe malaria and suggest that rosette-disrupting therapies could have
clinical benefit.17
A number of sulfated glycoconjugate drugs have been identified that disrupt rosettes18,19
and are plausible candidates for therapy.20,21 However, before clinical trials of rosette-
disrupting therapy can be considered, it is important to know which patients would be
appropriate targets for treatment. Currently it is unclear whether all severe malaria patients
might benefit from rosette-disrupting adjunctive therapies, or whether rosetting only occurs
at high levels in specific sub-categories of severe disease. Previous work on the association
between rosetting and severe malaria (Table 1) has tended to focus either on specific
syndromes such as cerebral malaria (unrousable coma) or on mixed groups of severe malaria
cases incorporating a variety of different clinical syndromes including cerebral malaria,
severe anemia, respiratory distress (difficulty breathing), and prostration (inability to sit, or
in infants, to breast feed).
To clarify the association of rosetting with different clinical forms of severe disease, we
carried out a detailed study of the factors affecting rosetting in a case-control study of severe
falciparum malaria in a moderately high malaria transmission area in sub-Saharan Africa,
carefully characterizing distinct clinical syndromes of uncomplicated and severe malaria.
MATERIALS AND METHODS
Study site and field isolates
Parasite isolates were collected as part of the Bandiagara Malaria Project case-control study.
22
-
24
 Bandiagara, Mali, is an area with intense seasonal transmission of P. falciparum (up to
20–60 infected bites per person per month at the peak of the July–December transmission
season).25 Community permission and individual written informed consent from the
patients' parents or guardians were obtained as described by Diallo et al.26 Protocols were
approved by the institutional review boards of the University of Mali (now University of
Bamako) Faculty of Medicine and the University of Maryland. Blood samples were
collected from children with malaria as described,22-24 and severe malaria was managed
following standardized protocols to initiate rapid treatment and prevent and treat
complications. Severe malaria syndromes were defined following World Health
Organization criteria,27 although patients with hyperparasitemia (> 500,000 parasites per
microlitre of blood) and no other symptoms or signs of severe disease were analyzed as a
separate group. Previous studies indicate negligible mortality for children with non-severe
hyperparasitemia,22,28 and this category can therefore be considered as a form of
uncomplicated malaria with particularly high parasite densities. Uncomplicated malaria
cases were children with P. falciparum infection and fever but with no symptoms or signs of
severe malaria and no hyperparasitemia. Sub-categories of severe malaria were cerebral
malaria (unrousable coma with a Blantyre Coma Score (BCS) of ≤ 2, with other obvious
causes of coma excluded), severe anemia (Hb < 5 g/dL), neurological impairment (impaired
consciousness or prostration but with a BCS of > 2), repeated seizures but no lasting
neurological impairment, and a small heterogeneous group with no neurological
abnormalities or anemia but with evidence of renal failure (anuria or hematuria) or jaundice.
Cerebral malaria and severe anemia were taken as primary defining criteria when they co-
existed with other criteria, as described previously.22 Respiratory distress did occur, but
always co-existed with other severe criteria such as coma, anemia, or neurological
impairment, therefore it is not shown as a separate category.
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Parasite culture
Blood samples were depleted of lymphocytes via density centrifugation, suspended in
Glycerolyte, and frozen to −70°C. Frozen samples were shipped to Edinburgh where they
were thawed by standard methods. Briefly, the isolates were diluted in a gradient of salt
solutions and washed in RPMI 1640 medium containing 2 mM glutamine, 25 mM Hepes, 20
mM glucose, and 25 μg/mL gentamicin (incomplete RPMI) before culturing in complete
RPMI (incomplete RPMI supplemented with 10% human AB serum) at 2% hematocrit. The
parasites were incubated at 37°C in 3% CO2, 1% O2, 96% N2. Cultures were monitored by
Giemsa-stained thin smears for 18–36 hours, and only those with normal morphology that
matured to the pigmented-trophozoite stage were included in the study. Two hundred and
seventy-two out of a possible 378 P. falciparum-infected samples collected as part of the
Bandiagara case-control study22 were put into culture, the remainder having been lost in a
freezer breakdown. The rosette frequency of 209 of these isolates was assessed, the
remainder being excluded either because the parasites failed to mature beyond ring stage in
vitro or because the parasitemia was too low for reliable assessment (< 0.5 %).
Rosetting assays
The rosetting of each isolate was assessed in the first cycle of in vitro growth when the
majority of the parasites had reached the pigmented-trophozoite stage. A 100 μL aliquot of
culture suspension was stained with 25 μg/mL of ethidium bromide for 5 minutes. A wet
preparation was made by placing a 10 μL drop of culture suspension (2% hematocrit) on a
microscope slide and covering it with a 22 × 22 mm coverslip. Wet preparation slides were
blinded so that the microscopist did not know the clinical category of each sample. The wet
preparation was viewed with a fluorescence microscope (40× objective) using both white
light and fluorescence simultaneously to visualize both infected and uninfected erythrocytes.
Mature-infected erythrocytes were counted and assessed for rosetting, with a rosette being
defined as an infected erythrocyte binding two or more uninfected erythrocytes. The rosette
frequency is the percentage of infected erythrocytes in rosettes out of 200 infected
erythrocytes counted.
Platelet-mediated clumping assays
Platelet-mediated clumping was assessed when the parasites reached the mature pigmented-
trophozoite stage as described previously.29 Briefly, parasite cultures were suspended at 2%
hematocrit in 10% platelet-rich plasma from an AB+ malaria-naive donor (to avoid ABO
compatibility problems) in incomplete RPMI medium (final concentration 1 × 107 platelets
per mL). Twenty-five μg/mL of ethidium bromide was added and the mixture was gently
rotated for 30 minutes at room temperature. A wet preparation was viewed on a fluorescence
microscope and 500 infected red cells were counted and scored for clumping, with three or
more infected erythrocytes adherent to each other constituting a clump. The clumping
frequency is the percentage of infected erythrocytes in clumps out of 500 infected
erythrocytes counted.
Statistical analysis
The original matched design of the Bandiagara case-control study22 was not used in the
rosette frequency analysis because technical problems (see parasite culture) meant that it
was not possible to obtain rosette frequency data from all samples. The χ2 test was
calculated using a 3 × 2 contingency table at http://www.physics.csbsju.edu/cgi-bin/stats/
contingency.html. Univariate analysis was carried out using Statview (version 5, SAS
Institute, Inc., Cary, NC), and multi variate analysis was carried out using the statistical
package S-PLUS 6.0 (Release 1, Insightful Corp., Palo Alto, CA), using Generalized Linear
Models (GLM). Because the response variables were proportions, and therefore bound
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between 0 and 1, they were analyzed using binomial errors with a logit linear predictor.30,31
The rosette frequency percentages were analyzed as counts with binomial errors.
Explanatory variables in the statistical model included category of disease (severe malaria,
non-severe hyperparasitemia, and uncomplicated malaria, as defined above), patient
parasitemia on admission to hospital (% of erythrocytes parasitized), parasite platelet-
mediated clumping frequency (%), patient ABO blood group, age, and hemoglobin level.
The analyses were repeated using only cases in the severe disease category. In these
analyses, rosetting was examined between subcategories of severe disease (which includes
coma, neurological impairment, seizures, anemia, and other), and sub-category replaced
category of disease as an explanatory term in the model. Models were fitted by initially
including all explanatory terms and allowing interactions up to second order. Interactions
including more than two terms were not permitted due to small sample sizes. The statistical
significance of a term in a GLM with binomial errors was assessed by the change in
deviance of the model when the term was dropped from it. To correct for overdispersion,
significance of a term was assessed using an F ratio. Minimal models were obtained by step-
wise deletion of non-significant terms, using an α-value of 0.05. Data on the relationship
between rosetting and ABO blood group using this dataset have been reported previously,16
and rosetting in relation to invasion properties of a subset of the samples has also been
described.24 However, the analysis presented here on the whole dataset and the relationship
between rosetting and sub-categories of severe malaria has not previously been reported.
RESULTS
Rosetting was assessed in the first cycle of in vitro growth in 209 P. falciparum isolates from
Malian children (91 from children with uncomplicated malaria, 40 from children with non-
severe hyperparasitemia, and 78 from children with severe malaria). The characteristics of
the patients from which the parasite isolates were derived are summarized in Table 2. The
children in the three disease categories did not differ significantly in age. The children with
severe malaria had lower hemoglobin levels than the other two groups, as expected because
severe anemia is a criterion for severe disease. The highest mean parasitemia was seen in
children with non-severe hyperparasitemia and the lowest in children with uncomplicated
malaria (Table 2), which is also as expected, because parasitemia was a defining feature of
these categories.
Rosetting was most common in parasite isolates from severe malaria patients (severe
malaria, rosettes in 70/78 (90%), non-severe hyperparasitemia 31/40 (77%), and
uncomplicated malaria 50/91 (55%) isolates, χ2 = 26.0, two degrees of freedom, P <
0.0001). Furthermore, examination of the distribution of rosette frequencies within each
disease category showed that the median rosette frequency in the severe disease category
(median 20%, interquartile range (IQR) 10–40%) was significantly higher than in the two
non-severe categories (hyperparasitemia: median 8.5%, IQR 2–20%; uncomplicated
malaria: median 1%, IQR 0–12%, Kruskal-Wallis test P < 0.0001, Figure 1).
Our previous work on platelet-mediated clumping (a parasite adhesion phenotype whose
relationship with disease severity remains controversial) showed that univariate analysis can
be misleading, and that apparent associations with disease category can arise if confounding
factors such as parasitemia differ between disease categories.29 To determine if other
variables influence the association between rosetting and severe malaria, we performed
multivariate analysis of factors that affect rosetting, including the disease category (severe,
non-severe hyperparasitemia, and uncomplicated), patient's admission parasitemia, patient
age, hemoglobin level, and ABO blood group type. The platelet-mediated clumping
frequencies of these clinical isolates had been measured previously,29 therefore parasite
clumping frequency was also included in the multivariate analysis, to investigate the
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relationship between clumping and rosetting. Multivariate analysis suggested that disease
category explained most of the deviance in rosetting, with highly significant differences in
rosetting demonstrated between categories (F2,117 = 8.15, P < 0.001). The other variable that
had a major effect on rosetting was ABO blood group (F3,117 = 3.54, P = 0.017), with lower
rosetting in isolates from group O patients compared with those from groups A, AB, and B
as reported previously.16 There was also an interaction between blood group and
hemoglobin, such that in blood group A and AB, rosetting frequency was negatively
associated with hemoglobin level, whereas this negative association was not apparent in
blood groups B and O (F3,117 = 4.88, P = 0.003). There was also evidence for a negative
association between rosetting and platelet-mediated clumping (F1,117 = 5.09, P = 0.026),
supporting the clear distinction between these two phenotypes. 29 Patient age and percentage
parasitemia on admission were non-significant terms in the model. In summary, this
multivariate analysis shows that disease category is the major factor affecting rosetting, and
indicates that the relationship between rosetting and severe disease is not due to confounding
factors such as host age or parasitemia.
To address whether rosetting is associated with distinct clinical forms of severe malaria,
rosette frequencies in the sub-categories of severe disease were examined. Within the severe
malaria category there were 26 children with unrousable coma (Blantyre coma score ≤ 2), 23
non-comatose children with impaired consciousness or prostration, 15 children with
repeated seizures, eight children with severe malarial anemia (Hb < 5 g/dL) and six children
with assorted other symptoms and signs suggestive of renal failure (anuria, hematuria) or
jaundice. High levels of rosetting were noted in each sub-category (Figure 2), and univariate
analysis demonstrated no significant differences between sub-categories (Kruskal-Wallis
test P = 0.63). There were five isolates from children who had both cerebral malaria and
severe malarial anemia, and these isolates were included in the cerebral malaria category for
analysis (Figure 2). However, inclusion of these five isolates in the severe anemia category
(giving a median rosette frequency 25%), or analyzing them as a separate group (median
rosette frequency 19%) did not materially alter the results shown here. The cerebral malaria
group had a median rosette frequency of 16% if the five isolates with concurrent severe
anemia were removed. Of the eight children in the severe anemia category, two also had
respiratory distress and one had hematuria. Nine children from the severe group died (11.5%
mortality), with the highest mortality rate occurring in children with coma plus severe
anemia (3/5, 60%). The median rosette frequency of the severe malaria patients who died
(20%, IQR 9.5–46.8%) was not significantly different from the median rosette frequency of
the severe malaria patients who survived (20%, IQR 10.0–37.8).
The multivariate analysis was repeated using the smaller dataset containing only the severe
malaria cases. As described in the full dataset, patient age and percentage parasitemia on
admission were non-significant terms in the model, whereas ABO blood group and platelet-
mediated clumping were significant factors. Importantly however, the multivariate analysis
confirmed that there were no significant differences in rosette frequency between the sub-
categories of severe disease (F4,67 = 1.28, P = 0.28).
DISCUSSION
This study confirms that high levels of rosetting are associated with severe malaria and
reveals that the association between rosetting and severe malaria remains highly statistically
significant after multivariate analysis that allows other factors such as patient parasitemia,
hemoglobin (Hb) level, and ABO blood group to be taken into consideration. In addition,
this study demonstrates, for the first time, that sub-categories of severe malaria all show
high levels of rosetting, with no statistically significant difference in rosette frequencies
between sub-categories (Figure 2).
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Early studies on rosetting and severe malaria focused on patients with strictly defined
cerebral malaria and showed markedly higher rosette frequencies in P. falciparum isolates
from comatose patients compared with isolates from patients with uncomplicated malaria in
West Africa (Table 1). 1,2 Studies in East Africa showed an association between rosetting
and cerebral malaria in some, 3,4 but not all studies. 5,8,32 Furthermore, an association
between rosetting and disease severity in mixed groups of severe malaria patients 3,6,7,9 or
patients with severe malarial anemia 5,8 was noted. Considerable uncertainty remains
regarding whether rosetting is associated with all clinical forms of severe malaria or only
some specific syndromes. The current study aimed to clarify the relationship between
rosetting and sub-categories of severe disease. We found high levels of rosetting in all sub-
categories of severe malaria in Mali, including cerebral malaria (coma), severe malarial
anemia, non-comatose neurological impairment (including prostration), repeated seizures
without long-lasting neurological impairment, and in a mixed group of patients with
symptoms or signs of renal failure or jaundice (Figure 2).
Despite the fact that this is one of the largest studies of rosetting and severe malaria carried
out to date, the sample size is still small in each sub-category of severe disease. This is
particularly true for the heterogeneous renal failure/jaundice sub-category, as these clinical
features are rare in African children with severe malaria. 28 Severe anemia is also relatively
uncommon in this study, due to the age distribution and epidemiology of severe disease in
the study area. 33 Neurological abnormalities are frequently seen in children with severe
malaria, and all manifestations (unrousable coma, non-comatose impaired consciousness,
and repeated seizures) were associated with high rosetting levels (Figure 2). Ideally, larger
studies should be carried out to confirm these results and to clarify the associations between
rosetting and severe malaria syndromes under different transmission intensities. However,
studies of rosetting and malaria severity are likely to remain problematic due to the logistical
difficulties of collecting and culturing large numbers of P. falciparum isolates from severely
ill children. Parasite isolates collected from patients have to be cultured in vitro for 12–36
hours before assessment of rosetting to allow development of ring-stage parasites (the only
form found in peripheral blood) to the pigmented-trophozoite stage at which rosetting
occurs. This process is time-consuming and requires facilities for cell culture and
microscopy that limit the sites at which studies can be undertaken.
Despite the logistic difficulties and small sample sizes affecting many rosetting studies, a
clear pattern emerges across sub-Saharan Africa. Children with uncomplicated malaria are
infected with parasite isolates that form few rosettes (Table 1 and Figure 1). In contrast,
most (although not all) children with severe malaria are infected with parasite isolates
showing high rosetting levels. In the current study, more than half of the severe malaria
cases had parasite isolates with rosette frequencies of 20% or higher. The rosette frequency
threshold at which pathogenic effects occur in vivo is unknown, and could be influenced by
numerous factors such as the patient's overall parasite burden, and the size and strength of
the rosettes. 34,35
Although the association between rosetting and severe malaria in sub-Saharan Africa is
well-established, direct evidence that rosetting plays a causal role in malaria pathogenesis in
humans is lacking. This is because experiments addressing the role of rosetting in
pathogenesis cannot be performed in humans for ethical reasons, and there is no animal
model that fully mimics the pathological and clinical features of falciparum malaria. There
is, however, strong indirect evidence from human genetic epidemiological studies that
supports a pathogenic role for rosetting. Human erythrocyte polymorphisms of rosetting
receptors that reduce the ability of P. falciparum to form rosettes, such as blood group O 4,14
and complement receptor 1 deficiency, 13 confer protection against severe malaria.
15
,
16
,
36
,
37
 These polymorphisms have a specific effect on rosetting and do not influence
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total parasite burdens, 15,16 therefore their protective effect is compelling evidence that
rosetting plays a causal role in pathogenesis. In addition, a plausible mechanism for a
pathogenic effect of rosetting has been demonstrated. In an ex vivo microvasculature model,
rosetting parasites cause significantly greater obstruction to flow in small blood vessels that
cytoadherent non-rosetting parasites. 10 In this model, rosettes were disrupted by high shear
forces in the arterial side of the circulation, but in capillaries and post-capillary venules,
rosetting parasitized erythrocytes bound to endothelial cells and uninfected erythrocytes
simultaneously to occlude vessels and impair blood flow. Impairment of microvascular
blood flow leading to hypoxia, ischemia, and metabolic disturbances is thought to be the
fundamental cause of tissue damage and death in severe malaria. 11,12 Taking all the above
data together, current evidence supports a direct role for rosetting in the pathogenesis of
severe malaria.
One unexpected result that emerged from the multivariate analysis of rosetting was an
interaction between ABO blood group and hemoglobin. Rosette frequency was negatively
associated with hemoglobin level in isolates from patients with blood groups A and AB,
whereas this negative association was not apparent in blood groups B and O (F3,117 = 4.88,
P = 0.003). Further investigation will be required to determine if this is a reproducible
finding and to examine its biological significance. Previous work has shown that rosetting
parasites show a preference for erythrocytes bearing either A or B blood group antigens, and
form larger, stronger rosettes with cells of the preferred type compared with group O cells.
14
,
38
 The preference for the A antigen is particularly common, 39 and direct binding of the
parasite rosetting ligand PfEMP1 to the A antigen has been demonstrated. 40 The
mechanism through which binding to A antigen (and rosetting in general) might lead to
lower hemoglobin levels is unclear. One possibility is that parasite-induced damage of the
uninfected erythrocytes in rosettes could occur, including the formation of oxidative
products such as 4-hydroxynonenal, 41 that could lead to the phagocytic clearance of
uninfected cells and so contribute to anemia. If rosettes in group A patients are larger (i.e.,
contain more uninfected erythrocytes per rosette than in B and O patients) this could lead to
greater clearance of uninfected erythrocytes and account for the relationship with
hemoglobin level seen here.
Recent research has identified compounds that reverse rosetting in vitro and may have
potential as adjunctive therapies for severe malaria. 20,21 The mortality rate of severe
malaria is as high as 15–20%, even in patients who reach hospital and are treated with
effective antimalarial drugs. Approximately 85% of severe malaria-related deaths in hospital
occur in the first 24 hours after admission, before the parasite-killing effects of antimalarial
drugs have time to act. 28 Therefore adjunctive therapies for severe malaria that target the
underlying disease process are urgently needed. 17 Rosette-disrupting therapies that relieve
or prevent microvascular obstruction have potential to ameliorate the symptoms of severe
malaria. Heparin has been shown to reverse rosetting in a subset (one-third to one-half) of
rosetting isolates, 18,19,42 and a heparin derivative reverses sequestration in an animal
model. 20 Curdlan sulfate, a glycoconjugate drug that was initially developed as a possible
AIDS therapy, 43 was shown to be an effective rosette-reversing agent against a range of
clinical isolates 21 and is another potential candidate for severe malaria adjunctive therapy.
Curdlan sulfate was shown to be safe for use in Thai adult patients with severe malaria, 44
however, rosetting is not associated with severe disease in this region (possibly due to
differing pathogenic mechanisms related to low levels of malaria transmission and
immunity, reviewed in reference 17). Curdlan sulfate has not yet been tested for its
effectiveness as an adjunctive therapy in the most appropriate patient population, i.e.,
children in sub-Saharan Africa. We have demonstrated that all clinical forms of severe
malaria are associated with high levels of rosetting in a sub-Saharan African study, which
suggests that all severe malaria syndromes in this region might benefit from rosette-
Doumbo et al. Page 7
Am J Trop Med Hyg. Author manuscript; available in PMC 2010 June 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
disrupting therapies. Clinical trials in well-defined patient populations in parallel with
further studies on parasite rosetting properties will be required to determine whether rosette-
reversing therapies can reduce the high mortality rate of severe malaria.
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Figure 1.
Distribution of P. falciparum field isolate rosette frequencies in relation to malaria severity.
Box plots showing significantly higher rosette frequencies in parasite isolates collected from
children with severe malaria (severe, N = 78) compared with isolates from children with
non-severe hyperparasitemia (hyp, N = 40) or uncomplicated malaria (uncomp, N = 91),
Kruskal-Wallis test, P < 0.0001. Boxes indicate the median (central line) and the
interquartile range. The error bar indicates the 90th percentile, and points beyond the 90th
percentile are shown as circles.
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Figure 2.
Distribution of P. falciparum field isolate rosette frequencies in relation to severe malaria
sub-categories. Box plots (as in Figure 1) showing no significant difference in rosette
frequencies between various severe malaria sub-categories including severe malarial anemia
(anemia, median 30.5%, interquartile range (IQR) 11–58%), cerebral malaria (coma, median
16.5%, IQR 4–28%), non-comatose neurological impairment (neuro, median 22.0%, IQR
13–45%), repeated seizures (seizures, median 22.0%, IQR 11–29%), and renal failure/
jaundice (other, median 9.5%, IQR 0–71%), Kruskal-Wallis test, P = 0.63. A full definition
of each sub-category is given in the methods. The number of isolates (N) in each
subcategory is shown. For comparison, the non-severe hyperparasitemia patients had a
median rosette frequency of 8.5%, IQR 2–20%, and the uncomplicated malaria patients had
a median rosette frequency of 1%, IQR 0–12%.
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Table 1
Rosetting and severe malaria in sub-Saharan Africa
Mean or median rosette frequency* (range)
Number of isolates
Site and reference Cerebral malaria† Severe malaria‡ Uncomplicated malaria§ P value
The Gambia1 35 (6–85) ND¶ 17 (0–71) < 0.001
24 57
The Gambia2 28.3 (0.5–70) ND 8.5 (0–55) < 0.000001
24 106
Madagascar3 19.5 (5–28) 30.5 (20–43) 5 (0–19) < 0.05 (CM vs. UM),
6 6 9 < 0.002 (SM vs. UM)
Kenya4 6 (0–94) 7 (0–97) 1 (0–82) < 0.003 (SM and CM vs. UM)
21 15 54
Kenya5 5.0 (0–37) 9.5|| (0–46) 4.5 (0–26) < 0.05 (SM vs. UM)
45 49 50 NS# (CM vs. UM)
Gabon6 ND 16 8 < 0.05
47 47
Malawi32 13.9 (0–57) 16.4|| (1–49) 15.0 (0–61) NS
46 18 62
Kenya7 ND 6.5** (2.0–34.9)†† 4.1 (0.9–10.8)†† 0.02/0.054‡‡
57 64
Kenya8 17.2 29.7|| 12.9 0.001 (SM vs. UM),
11 21 45 NS (CM vs. UM)
Kenya9 ND 14.0** (4–32)†† 3.5 (1–10)†† < 0.001
25 49
*
Rosette frequency = percentage of mature-infected erythrocytes binding two or more uninfected erythrocytes.
†CM, cerebral malaria is defined as unrousable coma (Blantyre coma score of two or less).
‡SM, severe malaria includes a variety of syndromes such as severe malarial anemia (Hb < 5 g/dL), respiratory distress, prostration, and
hypoglycemia.
§UM, uncomplicated malaria is defined as acute falciparum malaria with no complications of severe or cerebral disease.
¶ND = not determined.
||Severe malarial anemia only.
#NS = not significant.
**
Includes cerebral malaria cases.
††
Interquartile range.
‡‡
Mann Whitney U test/logistic regression.
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Table 2
Summary of patient characteristics
Disease category N Age* (months) Hb* (g/dL) Pt*† (%)
Uncomplicated malaria 91 42.9 (27.3) 9.8 (1.7) 2.0 (1.8)
Non-severe hyperparasitemia 40 47.2 (27.8) 10.2 (1.5) 12.6 (6.5)
Severe malaria 78 38.5 (25.3) 8.0 (2.5) 7.0 (6.5)
P value‡ 0.232 < 0.0001 < 0.0001
*
Mean (standard deviation).
†
Pt = parasitemia.
‡ANOVA.
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